SCHEMBL4756221

SCHEMBL4756221

CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CCC2(C1)OC(=O)c1cnccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.64
CYP2D6 P10635 2/20 0.47
ALDH1A1 P00352 4/20 0.46
LMNA P02545 3/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPY5R Q15761 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756211 1.00 HSD11B1 (0.64) HSD11B1CYP2D6ALDH1A1LMNAKDM4E
SCHEMBL6080897 0.88 HSD11B1 (0.61) HSD11B1CYP2D6ALDH1A1LMNAKDM4E
SCHEMBL6080875 0.88 HSD11B1 (0.61) HSD11B1CYP2D6ALDH1A1LMNAKDM4E
SCHEMBL4754460 0.86 HSD11B1 (0.67) HSD11B1CYP2D6NPY5R
SCHEMBL6080880 0.86 HSD11B1 (0.67) HSD11B1CYP2D6NPY5R
SCHEMBL4755714 0.84 HSD11B1 (0.45) HSD11B1CYP2D6ALDH1A1LMNAKDM4E
SCHEMBL6080148 0.80 HSD11B1 (0.54) HSD11B1CYP2D6NPY5R
SCHEMBL349442 0.78 HSD11B1 (1.00) HSD11B1CYP2D6
SCHEMBL6080429 0.78 HSD11B1 (0.51) HSD11B1CYP2D6NPY5R
SCHEMBL4757069 0.77 HSD11B1 (0.65) HSD11B1CYP2D6NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758582-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1758582-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP claimed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US claimed
WO-2006002349-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO claimed
EP-1758582-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1758582-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US disclosed
WO-2006002349-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009471-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885CYP2D6 358/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.